FDA Orphan Drugs Program and Financial Incentives for CDER Medical Products- June 10, 2019

Roberta Szydlo from FDA’s Office of Orphan Products Development discusses incentives for the development of products for the diagnosis and/or treatment of rare diseases or conditions. This includes orphan drug program tax credits, waivers, exclusivity, grants program, and rare pediatric disease designation.
Find more information at www.fda.gov/drugs/cder-small-...
_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Visit www.fda.gov/cdersbia and www.fda.gov/cdersbialearn for news and a repository of training activities.
Email: [e-mail]
Phone: [phone] I [phone]
LinkedIn: / cder-small-business-an...
Twitter: / fda_drug_info
CDER small business e-mail update subscription: updates.fda.gov/subscriptionm...